You may find more results for this query on our sister sites: 360Dx and Precision Oncology News.
As AstraZeneca takes steps to reintroduce the EGFR-targeted NSCLC drug in the US, Qiagen will develop a tissue-based molecular CDx to accompany the launch.
Cynvenio's LiquidBiopsy platform is designed to extract and isolate circulating tumor cells from a blood draw and prepare them for imaging and genomic analysis.
CEO Jay Flatley preannounced fourth-quarter revenues of $512 million and also unveiled the HiSeq X Five System, the HiSeq 3000 and 4000 Systems, and the NextSeq 550 System, an NGS system enabled for array scanning.
The partners hope to detect EGFR mutations in lung cancer patients using Trovagene's Precision Cancer Monitoring platform.
The assay analyzes circulating nucleic acids in blood samples to detect EGFR mutations in non-small cell lung cancer.
Exosome will use the ALCMI samples to support the validation of its ALK and EGFR T790M liquid biopsy tests, which the company plans to launch this year as LDTs.
Epic will now be able to participate in additional therapeutic clinical trials as a companion diagnostic partner.
The non-invasive, blood-based circulating tumor cell and circulating tumor DNA cancer tests will be made available to 19 million patients.
The Washington Post writes that the approval in the US of a SARS-CoV-2 vaccine will be up to Peter Marks, a career official at the Food and Drug Administration.
According to ScienceInsider, the US National Academies of Science, Engineering, and Medicine is planning a study of racism in academic research.
NPR reports the US loan to Eastman Kodak to boost domestic pharmaceutical production is on pause following insider trading allegations.
In Cell this week: blood immune cell changes in COVID-19 patients and spatial transcriptomics in Alzheimer's disease.